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Abstract
Background: Equine mesenchymal stromal/stem cells (MSCs) are most commonly harvested from bone marrow
(BM) or adipose tissue, requiring the use of surgical procedures. By contrast, the uterus can be accessed nonsurgically,
and may provide a more readily available cell source. While human endometrium is known to harbor mesenchymal
precursor cells, MSCs have not been identified in equine endometrium. This study reports the isolation, culture, and
characterization of MSCs from equine endometrium.
Methods: The presence of MSC and pericyte markers in endometrial sections was determined using
immunohistochemistry. Stromal cells were harvested and cultured after separation of epithelial cells from
endometrial fragments using Mucin-1-bound beads. For comparison, MSCs were also harvested from BM. The
expression of surface markers in endometrial and BM-derived MSCs was characterized using flow cytometry
and quantitative polymerase chain reaction. MSCs were differentiated in vitro into adipogenic, chondrogenic,
osteogenic, and smooth muscle lineages.
Results: Typical markers of MSCs (CD29, CD44, CD90, and CD105) and pericytes (NG2 and CD146) were
localized in the equine endometrium. Both endometrial and BM MSCs grew clonally and robustly expressed
MSC and pericyte markers in culture while showing greatly reduced or negligible expression of hematopoietic
markers (CD45, CD34) and MHC-II. Additionally, both endometrial and BM MSCs differentiated into adipogenic,
osteogenic, and chondrogenic lineages in vitro, and endometrial MSCs had a distinct ability to undergo
smooth muscle differentiation.
Conclusions: We have demonstrated for the first time the presence of cells in equine endometrium that fulfill
the definition of MSCs. The equine endometrium may provide an alternative, easily accessible source of MSCs,
not only for therapeutic regeneration of the uterus, but also for other tissues where MSCs from other sources
are currently being used therapeutically.
Keywords: Mesenchymal stem cells, Endometrium, Equine, Horse
Background
Considerable progress has been made in understanding
the biology and therapeutic potential of adult stem cells
since the first report of human hematopoietic stem cell
transplantation in 1957 [1]. Mesenchymal stem or stro-
mal cells (MSCs) were originally described in the 1960s
as a subset of fibroblast-like cells in the bone marrow
capable of undergoing osteogenic differentiation [2].
Minimum criteria defining human MSCs were estab-
lished by the International Society for Cellular Therapy
in 2006 [3] and include: plastic adherence under stand-
ard culture conditions; expression of the surface markers
CD73, CD90, and CD105 and lack of expression of
hematopoietic markers as well as HLA-DR; and ability
to undergo adipogenic, chondrogenic, and osteogenic
differentiation in vitro. In 2013, CD29 and CD44 were
added to the list of MSC-positive surface markers [4].
Furthermore, the origin of MSCs in multiple body tissues,
including human endometrium [5, 6], has been traced to
perivascular cells expressing CD146, NG2, PDGFRβ, and
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α-SMA. Expression of these markers is maintained by hu-
man MSCs in culture [7]. Moreover, studies in vitro and
using cell transplantation in model species have shown
that, in addition to providing different types of precursor
cells, MSCs contribute to tissue repair through immuno-
modulatory, antiapoptotic, antimicrobial, and a variety of
other trophic effects that act to enhance endogenous
repair mechanisms [8]. Based on these findings, several
hundred clinical trials are currently being carried out
using human MSCs [9].
In the horse, MSCs have been used clinically for about
15 years, with therapeutic benefit reported in the treat-
ment of several orthopedic conditions. Equine MSCs are
commonly harvested from bone marrow or adipose tis-
sue and are expanded in vitro before use in autologous
transplants [10–13]. The requirement to use surgical
procedures to harvest cells from those locations has
driven the search for other—less invasive—sources in-
cluding whole blood, umbilical cord blood, or Wharton
jelly [14–17]. In that regard, the endometrium represents
an attractive alternative source of MSCs in the horse.
Endometrial cells meeting the criteria of MSCs have
already been harvested and characterized from humans,
rodents, pigs, dogs, and sheep [18–25]. In addition to
undergoing trilineage differentiation, they can reportedly
generate muscle and neuronal lineages [5, 26]. The
therapeutic potential of endometrial MSCs has already
been demonstrated in relation to premature ovarian fail-
ure [27], Parkinson’s disease [26], and pelvic organ pro-
lapse [28], although these uses have yet to be proven
clinically.
The equine endometrium is highly dynamic, cyclically
undergoing remodeling [29] which suggests the presence
of an active population of mesenchymal precursor cells,
yet this has not been investigated. With the goal of
eventually exploring the therapeutic potential of these
cells, this study aimed to isolate and characterize equine
endometrial MSCs and compare their properties to those
of the well-characterized bone marrow (BM)-derived
MSCs.
Methods
Samples and materials
Equine reproductive tracts were collected post mortem
from five prepubertal (18-month-old) Welsh Cob ponies
and one 6-year-old warmblood mare during diestrus.
Bone marrow samples were collected from three Welsh
Cob ponies. The animals were euthanized at the School
of Veterinary Studies of the University of Edinburgh or
the School of Veterinary Medicine of the University of
Glasgow for reasons not related to any reproductive
tract pathology. All animal procedures were carried out
according to the UK Home Office Animals (Scientific
Procedures) Act 1986 with approval by the Ethical Review
Committee, University of Edinburgh (60/4207). All chemi-
cals and reagents used for cell culture in the study were
obtained from Life Technologies (Thermo Fisher Scien-
tific, Paisley, UK) unless otherwise specified, and culture
plastic ware (Nunc™) was purchased from Sigma Aldrich
(St Louis, MO, USA).
Immunohistochemistry
Small pieces of equine endometrium (5 mm× 5 mm)
were snap frozen and cut into 5-μm sections using a
Leica CM1900 cryotome. The tissue sections were fixed
in ice-cold methanol:acetone (50:50) for 10 minutes and
washed three times with phosphate buffered saline (PBS)
before incubation with a Protein Block (Spring Bioscience)
for 45 minutes at room temperature. The sections were
then incubated overnight at 4 °C with the primary anti-
bodies presented in Table 1. Another three washes with
PBS were followed by incubation with the secondary anti-
body (Table 1) for 30 minutes at room temperature. Fi-
nally, the nuclei were counterstained for 3 minutes with
4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI)
before mounting. Sections were visualized under a Leica
DM LB2 fluorescence microscope.
Isolation of equine endometrial stromal cells
One gram of endometrial tissue was stripped from the
underlying myometrium and dissociated using mechan-
ical and enzymatic digestion as described previously [20]
with a few modifications. In short, the tissue pieces were
washed twice in PBS and minced before dissociation in
DMEM/F-12 containing 0.1% bovine serum albumin
(BSA), 0.5% collagenase I, 40 μg/ml deoxyribonuclease
type I (Sigma Aldrich), and 1% penicillin/streptomycin
for 40 minutes at 37 °C in a SI50 Orbital Incubator (Stu-
art Scientific). The resulting cell solution was filtered
through a sterile 70-μm cell strainer (Fisher Scientific)
to separate single cells from undigested tissue fragments.
After washing with MSC culture medium consisting of
DMEM/F-12 containing 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin, and centrifugation for
5 minutes at 720 × g, the resulting cell pellet was resus-
pended in Ca2+ and Mg2+-free PBS supplemented with
0.1% FBS and 2 mM sodium citrate.
Magnetic Dynabeads M-450 that had been coated with
a Mucin-1 antibody (Santa Cruz) according to the man-
ufacturer’s protocol were utilized to remove epithelial
cells from the single cell suspension. The number of
Mucin-1-coated beads required was calculated assuming
50% of the cell suspension was epithelial. Four beads
were incubated per epithelial cell for 40 minutes at 4 °C
with gentle rotation and tilting. Unbound (stromal,
Muc-1–) and bound (epithelial, Muc-1+) cell fractions
were collected using a Dynamagnet 2, centrifuged, and
cultured in MSC culture medium at an initial density of
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106 cells/75 cm2 in a humidified incubator at 37 °C in
5%CO2:95% air. Medium was changed every 2–3 days.
Isolation of equine bone marrow-derived MSCs
Bone marrow was scraped out of the sternum and
immersed in 30 ml PBS containing 45 mg ethylenedi-
aminetetraacetic acid (EDTA) in a 50-ml Falcon tube.
The tube was gently rotated and tilted to wash out cells
from the bone marrow matrix. The solution was filtered
through a 40-μm cell strainer (Fisher Scientific) and cen-
trifuged at 720 × g for 5 minutes. The resulting cell pellet
was resuspended in PBS. To remove red blood cells,
4 ml of the BM cell solution was underlaid with 3 ml
Ficoll Paque PLUS (GE Healthcare) and centrifuged at
20 °C for 40 minutes at 400 × g. The interphase layer of
mononuclear cells was collected, washed twice with PBS,
and cultured at an initial density of 20–40 million cells/
175 cm2 in MSC culture medium under the same condi-
tions already described for the endometrial-derived stro-
mal cells.
Colony forming unit assay
Doubling times (DTs) of endometrial Muc-1– fraction
cells (n = 6 horses) and BM MSCs (n = 3 horses) in cul-
ture were calculated between passages 1 and 2 using the
following equation:
DT ¼ T ln2= ln Xe=Xbð Þ;
where T is the incubation time in days, and Xb and Xe
are the cell numbers at the beginning and the end, re-
spectively, of the incubation time.
Endometrial Muc-1– fraction cells and BM MSCs, both
at passage 2, were seeded in triplicate at clonal densities of
5 and 10 cells/cm2 in six-well plates and cultured in MSC
medium in a humidified atmosphere at 37 °C in 5%
CO2:95% air. Medium was changed every 3–4 days, and
on the 12th day of culture cells were washed with PBS and
fixed with 10% buffered formalin for 1 hour. Cultures were
then stained with crystal violet (Sigma Aldrich) for 10 mi-
nutes, washed three times with dH2O, and dried at room
temperature.
Cell clusters that were visible without magnification
and contained more than 50 cells were defined as col-
onies. Cloning efficiency (CE) was calculated with the
following formula:
CE ¼ number of colonies
number of cells seeded
⋅ 100
Flow cytometry
Endometrial Muc-1– cells (n = 6 horses) and BM MSCs
(n = 3 horses) at passage 3 or 4 were analyzed using flow
cytometry. The cultured cells were lifted with TrypLE,
Table 1 Antibodies selected for immunohistochemistry and flow cytometry characterization of equine MSCs
Antibody Host, isotype Epitope Clone Company
CD29 Mouse, IgG1,κ Human TS2/16 BioLegend
CD44 Mouse, IgG1 Horse CVS18 AbD Serotec
CD90 Mouse, IgG1,κ Rat OX-7 BD Pharmingen
CD105 Mouse, IgG1 Human SN6 AbD Serotec
NG2:APC Mouse, IgG1 Human LHM-2 R&D Systems
CD146:FITC Mouse, IgG1 Human OJ79c AbD Serotec
CD34:PE Mouse, IgG1 Human 4H11[APG] Immuno Tools
MHC-II:FITC Mouse, IgG1 Horse CVS20 AbD Serotec
Mucin-1 Goat, IgG Polyclonal Santa Cruz
Secondary antibodies
IgG—AF568 Donkey Mouse Polyclonal Invitrogen
IgG—AF488 Goat Mouse Polyclonal Invitrogen
IgG—AF568 Donkey Goat Polyclonal Invitrogen
Isotype controls
Mouse IgG1, κ MOPC-21 BioLegend
Mouse IgG1 11711 R&D Systems
Mouse IgG1:APC 11711 R&D Systems
Mouse IgG1:PE PPV-06 Immuno Tools
Mouse IgG1:FITC AbD Serotec
Goat IgG Santa Cruz
MSC mesenchymal stromal/stem cell
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washed with complete MSC culture medium, and centri-
fuged at 720 × g for 5 minutes at room temperature. Cell
pellets were resuspended in PBS containing 5% FBS and
incubated for 45 minutes on ice. Cells were then incu-
bated with directly conjugated or unconjugated primary
antibodies to different cell surface markers or with
matched isotype control IgG (Table 1) for 1 hour at 4 °C.
After three washes with PBS, cells were incubated with
AF488-conjugated secondary antibodies for 30 minutes at
4 °C. Cells were analyzed using a LSR Fortessa™ flow cyt-
ometer (BD Biosciences) equipped with FACS Diva soft-
ware and the collected data (10000 events) were analyzed
with FlowJo (V10; LLC).
Cross-reactivity of cell surface marker antibodies was
tested by IHC and flow cytometry, and the expression of
each marker was confirmed via RT quantitative polymer-
ase chain reaction (qPCR).
qPCR analyses
RNA was extracted using TRIzol reagent from freshly
collected endometrial cells (n = 6 horses) and from cul-
tures of endometrial Muc-1– cells (n = 6 horses) and BM
MSCs (n = 3 horses) at passages 1 and 4. RNA was ana-
lyzed using a spectrophotometer (ND-1000, Nano Drop®)
and total RNA (0.5–1 μg) was reverse-transcribed using
SuperScript III following the instructions of the manufac-
turer. Subsequent qPCR reactions were performed using
SensiFAST™ SYBR® Lo-ROX Kit (Bioline) and equine
primers (Table 2) in a Stratagene Mx3000P qPCR machine
(Agilent technologies). Data were analyzed with MxPRO
Table 2 Primers used for qPCR analysis
Marker Primer sequence (5′–3′)
Reference gene 18S Forward GCT GGC ACC AGA CTT G
Reverse GGG GAA TCA GGG TTC G
TBP Forward CCA AGC GTT TTG CTG TA
Reverse TTC ACT CTT GGC TCC CG
GAPDH Forward GAA GAT GTG GCG CGA TGG CC
Reverse ACT GAC ACG TTA GGG GTG GGG AC
MSC marker CD29 Forward GGC TAA CAG GGA GTT TCA GAT
Reverse ACA TCT ATT TTC ATC TGC TTG GC
CD44 Forward CCC ACG GAT CTG AAA CAA GTG
Reverse TTC TGG AAT TTG AGG TCT CCG TAT
CD90 Forward TGC GAA CTC CGC CTC TCT
Reverse GCT TAT GCC CTC GCA CTT G
CD105 Forward GAC GGA AAA TGT GGT CAG TAA TGA
Reverse GCG AGA GGC TCT CCG TGT T
Perivascular marker CD146 Forward CTG GAC TTG GAA ACC ACA ACA TC
Reverse CAG GTC TCA CTC GGA CAT CAG A
NG2 Forward CGA ATC ATT GGG CCC TAC TT
Reverse GCT GTT CCA CCT CTC TCC AG
Hematopoietic marker CD34 Forward CAC TAA ACC CTC TAC ATC ATT TTC TCC TA
Reverse GGC AGA TAC CTT GAG TCA ATT TCA
CD45 Forward TGA TTC CCA GAA ATG ACC ATG TA
Reverse ACA TTT TGG GCT TGT CCT GTA AC
Epithelial marker Mucin-1 Forward CTA TCT CGT TGC CCT GGC TG
Reverse GTA GGC ATC ACG GGT TGG AA
Smooth muscle marker ACTA2 Forward CTA ACA ACG TCC TCT CCG GG
Reverse CTG CTG GAA GGT GGA CAG AG
CNN1 Forward CGG CAA CTT CAT GGA CG
Reverse TTC TCC AGC TGG TGC CAA T
MHY11 Forward ATC CAT CCT GAC CCC ACG TA
Reverse CGG AAG AGC CGC TCA TAA GT
MSC mesenchymal stromal/stem cell, qPCR quantitative polymerase chain reaction
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qPCR software (Agilent technologies). Values were calcu-
lated relative to a standard curve prepared from a pool of
samples run simultaneously. Three reference genes were
analyzed for stability using the web-based comprehensive
tool RefFinder [30] integrating geNorm, BestKeeper,
Normfinder, and the comparative ΔCt method. Data were
normalized using RNA levels of 18S.
In-vitro trilineage differentiation
Endometrial Muc-1– cells and BM MSCs (from three
horses each) were used separately at passage 3 or 4. For
adipogenic differentiation, cells were seeded in triplicate
wells of 12-well plates (5000/cm2) with MSC culture
medium for 2–4 days before changing medium to
DMEM/F-12 containing 7% rabbit serum, 3% FBS, 1%
penicillin/streptomycin, 1 μM dexamethasone (Sigma
Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX)
(Sigma Aldrich), 10 μg/ml insulin (Sigma Aldrich), and
100 μM indomethacin (Sigma Aldrich). After 5 days of
culture, cells were washed with PBS before fixation in
10% formalin and were stained with Oil Red O (Sigma
Aldrich) for 10 minutes.
For osteogenic differentiation, cells were seeded in
triplicate wells of 12-well plates (5000 cells/cm2) and
cultured for 2–4 days before changing medium to
DMEM/F-12 containing 10% FBS, 1% penicillin/strepto-
mycin, 10 mM β-glycerophosphate (Sigma Aldrich), 100
nM dexamethasone (Sigma Aldrich), and 200 μML-as-
corbic acid 2-phosphate (Sigma Aldrich). Medium was
changed every 2–3 days and after 3 weeks cells were
washed with PBS, fixed in 10% formalin, and stained
with Alizarin Red (Sigma Aldrich) for 45 minutes.
For chondrogenic differentiation, 3 × 105–4 × 105 cells
were centrifuged in a V-bottomed 96-well plate at 720 × g
for 5 minutes. After centrifugation, without disturbing the
freshly formed pellet, medium was changed to DMEM/F-
12 containing 1% penicillin/streptomycin, 1% ITS+ premix
(Corning), 100 nM dexamethasone (Sigma Aldrich),
200 μML-ascorbic acid 2-phosphate (Sigma Aldrich),
100 μg/ml sodium pyruvate (Sigma Aldrich), and 10 ng/ml
TGF-β1 (R&D Systems). After 24 hours of incubation, the
pellets were gently loosened and transferred to a U-bottom
96-well plate with a cell-repellent surface (Greiner bio-one).
Micro masses were cultured for 28 days with medium
changes every 1–2 days and then fixed in 10% formalin for
24 hours. The pellets were processed and embedded in par-
affin. Sections were cut on a microtome (Leica RM2235)
and stained with Alcian Blue (Acros Organics) and the nu-
clear counter stain Nuclear Fast Red (Sigma Aldrich).
In-vitro smooth muscle differentiation
The protocol used for smooth muscle differentiation was
adapted from Guo et al. [31]. In short, endometrial Muc-1–
cells and BM MSCs (from three horses each) at passage 3
or 4 were seeded at a density of 70,000 cells/well in tripli-
cate wells of 12-well plates and incubated at 37 °C in
5%CO2:95% air for 24 hours before the medium was chan-
ged to DMEM containing 1% FBS. After a further 24 hours,
differentiation was induced by changing the medium to
DMEM containing 1% FBS and 1 ng/ml TGF-β1 (R&D
Systems). Control cells were maintained in MSC culture
medium and after 7 days all cells were harvested using
TRIzol reagent and processed for qPCR analysis as de-
scribed earlier.
Statistical analysis
All data were analyzed using IBM SPSS Statistics 22
software using each donor horse as the experimental
unit. Normal distribution was tested with the Shapiro–
Wilk test and data were log-transformed if necessary.
Flow cytometry data were analyzed using Levene’s test
for equality of variances and a two-tailed t test. QPCR
data were analyzed with two-way ANOVA and Tukey’s
test. Data are shown as mean ± SEM. Significance was
set at p < 0.05.
Results
Localization of MSC and perivascular markers in equine
endometrium
Endometrial tissue was analyzed for the presence of a selec-
tion of cluster of differentiation (CD) antigens commonly
used to identify human MSCs, namely CD29, CD44, CD90,
and CD105 (Fig. 1a), as well as the perivascular cell surface
markers, CD146 and NG2 (Fig. 1b). CD29 and CD44 were
localized mainly around blood vessels. Milder staining for
CD29 was found around endometrial glands and under-
neath the epithelium. CD90 clone 5E10 was very abundant
throughout the stroma, except in glandular cells (data not
shown), indicating lack of specificity. CD90 clone OX7
staining was present throughout the endometrial stroma in
a string-like pattern, and also around endometrial glands.
CD105 staining was less abundant and localized within sin-
gle cells throughout the stroma. All MSC markers tested
were absent from glandular cells and the endometrial epi-
thelium. The perivascular markers, CD146 and NG2, were
mostly located around the blood vessel walls.
Isolation and culture of endometrial MSCs
Culture of endometrial tissue directly following collage-
nase dissociation resulted in epithelial cells adhering
quickly to plastic culture ware and eventually outgrow-
ing the stromal cells (Fig. 2a). Thus, we used magnetic
beads bound to Muc-1, a surface marker located within
the luminal and glandular epithelium (Fig. 2b), to enrich
endometrial digests for stromal cells. The resulting Muc-1–
fraction, from here onward referred to as endometrial
MSCs, was used for culture (Fig. 2c).
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Upon initial seeding, endometrial MSCs attached quickly
and evenly over the entire culture surface in contrast to
BM MSCs which took longer to adhere and tended to grow
in clusters. Moreover, doubling times between passages
1 and 2 tended to be shorter for endometrial MSCs
than for BMMSCs (2.8 ± 0.6 vs 5.2 ± 1.9 days, respectively,
p = 0.09). Cloning efficiency (CE) assays performed at pas-
sage 2 yielded similar results for both endometrial and
BM MSCs, as shown in Fig. 2e, f.
Expression of MSC and perivascular markers by
endometrial MSCs in culture
The expression of MSC and perivascular cell surface
markers was analyzed by qPCR and flow cytometry in
endometrial and BM MSCs at different passages (Figs. 3
and 4). Moderate differences were detected in transcript
levels of MSC markers, including higher overall levels of
CD29 and, to a lesser degree, CD105, in endometrial
MSCs than in BM MSCs (as indicated in each case by a
significant effect of cell type), as well as a slight reduc-
tion in overall CD29 levels between passages 1 and 4
(Fig. 3). Flow cytometry (Fig. 4) showed all of these
markers to be present, on average, in ≥97% of endomet-
rial and BM MSCs (except for CD105, detected in 80%
of BM MSCs). Moreover, there was an overall increase
in transcript levels of CD146 between passages 1 and 4
(Fig. 3). The levels of another perivascular marker, NG2,
did not change with passage but were lower in endomet-
rial MSCs than in BM MSCs (Fig. 3), a result that was
confirmed by flow cytometry data (Fig. 4). Finally, CD34
and MHC-II were expressed by a minority of cells (≤2%)
in both endometrial and BM MSC cultures (Fig. 4),
whereas CD45 was detectable in BM MSCs at passage 1
only (Fig. 3).
In-vitro differentiation of endometrial MSCs
The ability of endometrial MSCs to undergo trilineage
differentiation was assessed in parallel with that of BM
MSCs. Endometrial MSCs differentiated into adipogenic,
osteogenic, and, albeit to a lesser degree than BM MSCs,
chondrogenic lineages (Fig. 5).
Additionally, the relative capacity of the two types of
MSCs to differentiate into smooth muscle, a key compo-
nent of the myometrium in the uterus, was determined
by treating cells with TGF-β1. Endometrial MSCs, but
not BM MSCs, underwent morphological changes pri-
marily characterized by shortening of the cell body in re-
sponse to treatment (Fig. 6a, b). Because of the difficulty
of clearly distinguishing smooth muscle cells from undif-
ferentiated MSCs, we assessed the expression of early
(ACTA2), intermediate (CNN1), and mature (MYH11)
smooth muscle markers [31] in endometrial and BM
MSC cultures by qPCR (Fig. 6c). Results showed an in-
crease in mean transcript levels of the intermediate
marker, CNN1, in BM MSCs (1.7-fold, p < 0.05) and,
particularly, in endometrial MSCs (2.9-fold, p < 0.0001)
between days 0 and 7, and an increase in the levels of
the mature smooth muscle marker, MYH11, only in
endometrial MSCs (1.8-fold, p < 0.005).
Discussion
MSCs—defined by their adherence to plastic, expression
of a subset of cell surface markers, and ability to differ-
entiate into adipogenic, osteogenic, and chondrogenic
lineages [3]—have to this date been isolated from several
body tissues including bone marrow, fat, umbilical cord,
placenta, amniotic fluid, umbilical cord blood, peripheral
blood, and endometrium [32–35]. Bone marrow and adi-
pose tissue have been the most common sources of clin-
ical MSCs in horses, and they are also the most common
sources used for clinical trials in humans. Collection of
MSCs from these locations requires relatively invasive
procedures involving sedation and local anesthesia, and
carries the potential of postsurgical complications [36].
Thus, alternative sources of equine MSCs, such as the
endometrium, are desirable. A major advantage of isolat-
ing MSCs from the endometrium compared to bone mar-
row or adipose tissue is that cells can be harvested by
biopsy collection [24, 37], which is a relatively noninvasive
approach used routinely in horses for diagnostic purposes
that does not require sedation or local anesthesia [38]. In
Fig. 1 Immunohistochemistry of equine endometrial sections.
Photomicrographs show localization of (a) MSC markers CD29, CD44,
CD90, and CD105 and (b) perivascular markers NG2 and CD146
within the equine endometrium. DAPI was used to stain cell nuclei.
Yellow arrows, endometrial glands; white arrows, blood vessels. DAPI
4′,6-diamidine-2′-phenylindole dihydrochloride (Color figure online)
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this study, we show for the first time that putative MSCs
contained within the equine endometrium can be har-
vested and expanded in vitro, and have characteristics that
may prove useful for tissue regeneration applications.
Endometrial MSCs had typical spindle-shaped morph-
ology, indistinguishable from that of BM MSCs; however,
they tended to grow faster than BM MSCs following initial
seeding, as indicated by their mean doubling time values.
In contrast, cloning efficiencies (CE) at passage 2 were
similar for the two cell types, around 25–30%, and com-
parable to previous reports from 27% [39] to 34% [40] for
equine BM MSCs. The faster initial growth of endometrial
MSCs relative to BM MSCs may be conferred by their na-
tive in-vivo environment characterized by fast tissue turn-
over during the estrous cycle. If confirmed in future
studies, this property of endometrial MSCs may provide
an advantage over other MSC sources because it may
allow shortening of the interval between collection of tis-
sue samples and transplant of in-vitro expanded MSCs,
which is a serious limitation of current BM and adipose
MSC treatments in horses. In addition, based on cell yields
obtained from 1 g of endometrial tissue (≥107 Muc-1–
cells) and considering subsequent growth rates in culture
(see Results), we estimate that a typical 0.2–0.4 g biopsy
would readily yield >10 million cells after short-term ex-
pansion, a sufficient number for therapy applications in
horses. Furthermore, when executed appropriately, the
biopsy procedure does not result in damage or scarring
of the uterus. Indeed, it has been shown that repeated
collection of multiple biopsies (up to five each time)
before estrus had no effect on subsequent pregnancy
rates in mares [41].
Cells staining for CD44, CD105, CD146, and NG2 were
located primarily around blood vessels within the equine
Fig. 2 Isolation and culture of MSCs. a Micrograph showing cells cultured directly following digestion of equine endometrium. Using this
procedure, clusters of epithelial cells (black arrows) eventually outgrew stromal cells in culture. b Section of equine endometrium stained for
Mucin-1, showing positive cells in epithelia and glands (white arrows). Cell nuclei stained with DAPI. c Micrograph of endometrial stromal cells in
culture obtained after separation of epithelial cells (shown in d) using beads bound to Mucin-1. e Cell colonies produced after seeding of
endometrial and BM MSCs at low densities. f Cloning efficiencies (CE) for endometrial MSCs (n = 6 horses) and BM MSCs (n = 3 horses) at two
different seeding densities. Scale bars: 1 mm (a, c–e). BM bone marrow, MSC mesenchymal stromal/stem cell (Color figure online)
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endometrium, consistent with the identification of perivas-
cular cells as native counterparts of MSCs in many differ-
ent human tissues [7, 42], including the endometrium [6].
By contrast, CD90 (clone OX7) followed a less restricted
pattern throughout the stroma to include nonperivascular
cells. The distinct abundance of CD90 compared to
the other MSC markers tested suggests that this may
not be an appropriate marker for equine MSCs in the
endometrium.
Consistent with the definition of MSCs, endometrial
stromal cells robustly maintained the expression of CD29,
CD44, CD90, and CD105 in culture, as well as, to a lesser
extent, perivascular markers, whilst having negligible
expression of hematopoietic markers and MHC-II, in
Fig. 3 Transcript levels (arbitrary units) of cell surface markers in cultured MSCs. Expression of MSC markers (CD29, CD44, CD90, CD105),
perivascular markers (NG2, CD146), and hematopoietic markers (CD34, CD45) quantified by qPCR in endometrial MSCs (n = 6 horses, white bars)
and BM MSCs (n = 3 horses, gray bars) in culture at passages 1 and 4. All results shown as mean ± SEM. Significant main effects (p < 0.05) of
passage, cell type, and passage × cell type interaction obtained by two-way ANOVA are shown. AU arbitrary units
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Fig. 4 Flow cytometry analysis. Representative flow cytometry histograms with percentages of endometrial and BM MSCs (n = 6 and n = 3 horses,
respectively) positive for different MSC, perivascular, and hematopoietic cell surface markers. Grey areas, signal from isotype controls; black lines,
signal from the specific cell surface marker. BM bone marrow, MSC mesenchymal stromal/stem cell
Fig. 5 Trilineage differentiation of endometrial MSCs (a, c, e) and BM MSCs (b, d, g). Representative images of endometrial and BM MSCs (n = 3
horses each) after differentiation and staining with Oil red O (a, b), Alizarin Red (c, d) and Alcian Blue/Nuclear Fast Red (e–g) to assess differentiation
into adipogenic, osteogenic, and chondrogenic lineages, respectively. Insets show nondifferentiated control cells (a–d). Nondifferentiated control BM
MSCs used in chondrogenic differentiation experiments shown in (f). Scale bars: 100 μm (a, b), 500 μm (c, d, e, g) and 1 mm (f)
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agreement with previous studies with human endometrial-
derived MSCs [5, 25, 27, 43]. A limited number of studies
have compared the features of endometrial MSCs with
MSCs from other sources [23, 44]. Our finding based on
results of flow cytometry and qPCR, showing that endo-
metrial MSCs in culture display moderately higher levels
of CD29, CD90, and CD105 but lower levels of NG2 than
their BM counterparts, is consistent with data from Indu-
mathi et al. [23]. Whether this is indicative of differences
in the abundance of stem cells between the two tissue
sources or reflects tissue-specific changes in immunophe-
notype that may be induced in culture should be investi-
gated in future studies.
That endometrial and BM MSCs have different proper-
ties was confirmed by the results of differentiation assays;
specifically by the observation that while endometrial
MSCs were able to undergo trilineage differentiation, their
ability to generate cartilage was lower than that of BM
MSCs based on a clearly reduced intensity of Alcian Blue
staining in endometrial MSC-derived chondrogenic pellets
(Fig. 5). In contrast, the opposite was observed in relation
to the ability of MSCs to adopt a smooth muscle pheno-
type, as evidenced by a distinct increase in endometrial
MSCs, but not in BM MSCs, in the levels of the mature
smooth muscle marker, MYH11, after treatment with
TGF-β1. There is evidence that significant differentiation
bias can be conferred by the tissue of origin of MSCs [45].
For example, while human multipotent cell populations
from the myometrium and skeletal muscle had a similar
immunophenotype and ability to differentiate into smooth
muscle, only skeletal muscle-derived progenitors were able
to undergo osteogenic and adipogenic differentiation [46].
In light of this, a distinct ability of endometrial MSCs
(compared to BM MSCs) to differentiate into smooth
muscle may be related to the presence of a large smooth
muscle component in the uterus, the myometrium.
Whether our observation alternatively reflects the pres-
ence, natural or through contamination during sample
collection, of myometrial precursor cells, different from
MSCs, in the endometrial stroma needs to be investigated
in future studies. Nonetheless, a reported intrinsic ability
of human endometrial MSCs to differentiate into smooth
muscle provides the rationale for specific therapeutic ap-
plications already being sought for these cells (e.g., pelvic
organ prolapse) [47].
Conclusion
We report for the first time the identification, culture,
and characterization of stromal cells within the equine
uterus that fulfill the definition of MSCs based on clono-
genicity, immunophenotype, and ability to differentiate
into different mesenchymal derivatives. Although not
addressed in this study, the relative abundance and
phenotype of MSCs in the equine endometrium may
vary with the reproductive stage, a possibility that should
be investigated in the future. Endometrial MSCs may
provide an easily accessible alternative to therapeutic ap-
plications that currently use bone marrow and adipose
Fig. 6 Smooth muscle differentiation. Micrographs showing (a) endometrial MSCs (n = 3 horses) and (b) BM MSCs (n = 3 horses) induced to
differentiate into smooth muscle for 7 days. Insets show noninduced control cells. Scale bars: 500 μm. c Expression of smooth muscle markers in
endometrial MSCs (white bars) and BM MSCs (grey bars) before (d0) and on day 7 (d7) of differentiation. Results shown as mean ± SEM. Significant
main effects (p < 0.05) of day, cell type, and day × cell type interaction obtained by two-way ANOVA are shown. AU arbitrary units
Rink et al. Stem Cell Research & Therapy  (2017) 8:166 Page 10 of 12
MSCs in the horse. They may moreover provide a new
therapeutic venue for equine uterine disease, a multifa-
ceted and highly prevalent condition which significantly
impairs fertility in mares. With this in mind, future stud-
ies should be aimed at exploring the clinical regenerative
potential of these cells in the endometrium but also in
other tissues that have been more commonly targeted
with cell therapies, such as musculoskeletal tissue.
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